8-K: Amylyx Pharmaceuticals to Acquire Avexitide Assets from Eiger BioPharmaceuticals for $35.1 Million Plus Liabilities

Amylyx Pharmaceuticals has agreed to purchase substantially all assets related to Eiger BioPharmaceuticals' Avexitide for $35.1 million, plus certain costs and assumed liabilities, pending bankruptcy court approval.

Summary

• Amylyx Pharmaceuticals has entered into an agreement to acquire the assets related to Avexitide from Eiger BioPharmaceuticals for $35.1 million, plus the cost of curing certain contracts and assuming certain liabilities.
• The deal is contingent on bankruptcy court approval, as Eiger BioPharmaceuticals filed for Chapter 11 bankruptcy on April 1, 2024.
• The assets include inventory, contracts, intellectual property, regulatory information, and business records related to Avexitide.
• Amylyx will assume certain liabilities associated with the acquired assets, while Eiger will retain all other liabilities.
• The agreement includes customary representations and warranties, and is subject to several closing conditions, including court approval and third-party consents.
• A deposit of $1.755 million has been placed in escrow, which will be released to Eiger upon closing or to Amylyx if the deal does not close due to certain reasons.
• The purchase price will be allocated for tax purposes, and both companies will cooperate to minimize transfer taxes.
• The deal is expected to close after all conditions are met, potentially by August 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it represents a strategic acquisition for Amylyx, but it is tempered by the uncertainties associated with Eiger's bankruptcy and the need for court approvals. The deal structure appears to be well-defined and protective of Amylyx's interests.

Positives

• Amylyx is acquiring a potentially valuable asset in Avexitide, which could expand their product portfolio.
• The deal is structured to minimize financial risk for Amylyx, with a defined purchase price and assumption of specific liabilities.
• The agreement includes provisions for the orderly transfer of regulatory approvals and intellectual property.
• The deal includes a termination fee payable to Amylyx if Eiger enters into an alternate transaction, providing some protection for Amylyx's investment.

Negatives

• The acquisition is contingent on bankruptcy court approval, which introduces uncertainty.
• Eiger's financial difficulties and bankruptcy filing could pose risks to the smooth transfer of assets.
• The deal involves the assumption of certain liabilities, which could impact Amylyx's financial position.
• There is a risk that third-party consents may not be obtained, potentially delaying or preventing the closing.

Risks

• The bankruptcy court may not approve the sale, or may approve it on terms unfavorable to Amylyx.
• Third-party consents required for the transfer of contracts and assets may not be obtained.
• There is a risk of delays in the closing process due to the bankruptcy proceedings.
• The assumed liabilities could be higher than anticipated, impacting Amylyx's financial performance.
• The value of the acquired assets may be lower than expected due to Eiger's financial situation.

Future Outlook

The document contains forward-looking statements regarding the completion of the acquisition, which is subject to risks and uncertainties, including bankruptcy court approval and the satisfaction of closing conditions. The company undertakes no obligation to update these statements.

Management Comments

• The document does not contain any direct quotes from management, but it does outline the terms and conditions of the agreement, which reflects management's decisions and strategies.

Industry Context

This acquisition reflects a trend of pharmaceutical companies acquiring assets to expand their pipelines and product portfolios. Amylyx is likely seeking to leverage Avexitide's potential in a specific therapeutic area, while Eiger is divesting assets as part of its bankruptcy proceedings.

Comparison to Industry Standards

• The structure of the deal, including the use of an escrow account and a termination fee, is consistent with industry standards for asset acquisitions, particularly in distressed situations.
• The due diligence process and the inclusion of representations and warranties are standard practices in such transactions.
• The requirement for bankruptcy court approval is a unique aspect of this deal, reflecting Eiger's financial situation.
• The timeline for closing, with a target date of August 31, 2024, is typical for complex transactions involving regulatory and court approvals.
• The allocation of purchase price for tax purposes is a standard practice in asset acquisitions.

Legal Proceedings

• Eiger BioPharmaceuticals filed for Chapter 11 bankruptcy on April 1, 2024, which necessitates bankruptcy court approval for the asset sale.

Stakeholder Impact

• Shareholders of Amylyx may view the acquisition positively if it enhances the company's growth prospects.
• Employees of Amylyx may be impacted by the integration of the acquired assets and operations.
• Eiger's creditors will be impacted by the sale of assets as part of the bankruptcy proceedings.
• Customers and suppliers of Eiger related to Avexitide will transition to Amylyx.

Next Steps

• Obtain bankruptcy court approval for the sale.
• Secure third-party consents for the transfer of contracts and assets.
• Complete the transfer of regulatory approvals and intellectual property.
• Finalize the allocation of the purchase price for tax purposes.
• Close the transaction by the target date of August 31, 2024.

Key Dates

Keywords

Amylyx Pharmaceuticals, Eiger BioPharmaceuticals, Avexitide, Asset Purchase Agreement, Bankruptcy, Acquisition, Intellectual Property, Regulatory Approvals, Chapter 11, Cure Costs